Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Phase 2 Completed
80 enrolled 13 charts
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Phase 2 Completed
96 enrolled 11 charts
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Phase 2 Completed
49 enrolled 21 charts
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
Phase 2 Terminated
14 enrolled 10 charts
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Phase 2 Completed
213 enrolled
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Withdrawn
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
47 enrolled 10 charts
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
Phase 2 Completed
175 enrolled
Use of Topotecan in Patients With Refractory Acute Leukemia
Phase 2 Completed
10 enrolled
Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
Phase 2 Unknown
20 enrolled
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Phase 2 Completed
3 enrolled
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab
Phase 2 Terminated
15 enrolled 5 charts
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase 2 Unknown
50 enrolled
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
Phase 2 Completed
3 enrolled